MetaCap

CytomX Therapeutics (CTMX) vs Indaptus Therapeutics (INDP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Indaptus Therapeutics (INDP) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 52.4% versus a loss of 47.7%. Over five years, CTMX leads with a -69.9% price change compared with -98.3% for INDP. CytomX Therapeutics is the larger company by market cap ($442.5 million vs $433.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTMX-47.68%INDP+52.43%
+167%+53%-62%
Nov 21, 20251 yearNov 20, 2026
CTMX-72.34%INDP-98.22%
+14%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTMX versus INDP key metrics
MetricCTMXINDP
Share price$2.03$2.82
Market cap$442.55M$433.16M
1-day change-0.98%-9.90%
YTD return-52.35%-3.09%
1-year return-47.68%+52.43%
5-year return-69.93%-98.26%
EPS (TTM)$-0.51$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$76.20M—
Revenue growth (YoY)-44.82%—
Net income (latest FY)$-17.37M$-20.85M
Operating margin-29.35%—
Net margin-22.79%—
52-week high$8.21$5.96
52-week low$1.87$0.92
Distance from 52-week high-75.27%-52.68%
Analyst consensusstrong_buy—
Avg. price target upside+509.85%—
Average volume4.27M712.87K
Shares outstanding218.00M153.60M
Employees695
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INDP has outperformed CTMX by 100.1 percentage points over the past year.

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Indaptus Therapeutics

INDP stock →

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CTMX vs INDP FAQ

Which is bigger, CytomX Therapeutics or Indaptus Therapeutics?

CytomX Therapeutics (CTMX) is larger, with a market capitalization of $442.55M compared with $433.16M for Indaptus Therapeutics (INDP).

Which stock has performed better over the past year, CTMX or INDP?

INDP returned +52.43% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Are CytomX Therapeutics and Indaptus Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons